2. Search Result
Search Result
Pathways Recommended: Stem Cell/Wnt Cell Cycle/DNA Damage
Results for "

mammary cell

" in MedChemExpress (MCE) Product Catalog:

17

Inhibitors & Agonists

1

Peptides

6

Natural
Products

1

Antibodies

2

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-W011527
    Xanthosine
    2 Publications Verification

    		 Endogenous Metabolite Metabolic Disease
    Xanthosine is a nucleoside derived from xanthine and ribose. Xanthosine activates the AMPK/FoxO1/AKT/GSK3β signaling cascade. Xanthosine promotes cell proliferation and regulates blood glucose metabolism. Xanthosine increases milk production in cows and goats. Xanthosine is used in mammary stem cell and type 2 diabetes research .
    Xanthosine
  • HY-100395
    F16

    		Apoptosis Cancer
    F16 is a potent growth inhibitor of the neu-overexpressing cells and also selectively inhibits proliferation of mammary epithelial as well as a variety of mouse mammary tumor and human breast cancer cell lines.
    F16
  • HY-W029411
    4-(Benzo[d]oxazol-2-yl)aniline

    		Drug Derivative Cancer
    4-(Benzo[d]oxazol-2-yl)aniline is a potent antitumor agent. 4-(Benzo[d]oxazol-2-yl)aniline has inhibitory activity against mammary carcinoma cell lines .
    4-(Benzo[d]oxazol-2-yl)aniline
  • HY-W010128
    6-(Dimethylamino)purine

    6-Dimethylaminopurine; 6-DMAP

    		 CDK DNA/RNA Synthesis Apoptosis Cancer
    6-(Dimethylamino) purine (6-Dimethylaminopurine) is a serine threonine protein kinase inhibitor. 6-(Dimethylamino) purine can inhibit prolactin induced expression of lactoprotein genes in rabbit mammary gland cells. 6-(Dimethylamino) purine can affect the maturation of mammalian oocytes. 6-(Dimethylamino) purine can lead to downregulation of genes related to cell proliferation and cell cycle progression, such as proliferating cell nuclear antigen, insulin-like gene 1, and serine protease inhibitor 2 genes, and induce apoptosis in lymphoma cells (apoptosis) .
    6-(Dimethylamino)purine
  • HY-145269
    AL-GDa62

    		Cadherin Cancer
    AL-GDa62 is a derivative of the CDH1/E-cadherin modulator SLEC-11 (HY-145268) and induces apoptosis in CDH1 -/- cells. AL-GDa62 has an EC50 of 3.2 μM and 2 μM for isogenic mammary epithelial cells MCF10A-WT (wild type) and mutant MCF10A-CDH1 -/-, respectively. AL-GDa62 specifically inhibits TCOF1, ARPC5, and UBC9, and suppresses SUMOylation at low micromolar concentrations .
    AL-GDa62
  • HY-W013803
    Xanthosine dihydrate

    		Endogenous Metabolite Metabolic Disease
    Xanthosine dihydrate is a nucleoside derived from xanthine and ribose. Xanthosine dihydrate can increase mammary stem cell population and milk production in cattle and goats .
    Xanthosine dihydrate
  • HY-N5166
    Ardeemin

    (-)-Ardeemin

    		 P-glycoprotein Cancer
    Ardeemin ((-)-Ardeemin) binds to the P-glycoprotein, preventing anticancer agent from being pumped out of cells. Ardeemin reverses the multidrug resistance phenotype of tumor cells and increases the sensitivity of tumor cells to anticancer agent in mammary carcinoma xenografts .
    Ardeemin
  • HY-P4115
    CooP

    		FABP Cancer
    CooP is a linear glioblastoma-targeting nonapeptide. CooP binds to the mammary-derived growth inhibitor/fatty acid binding protein 3 (FABP3) in the glioblastoma cells and its associated vasculature. CooP is used for the targeted delivery of chemotherapy and different nanoparticles .
    CooP
  • HY-124178
    (R)-Levrazoxane

    (R)-ICRF 186

    		 Drug Intermediate Metabolic Disease
    (R)-Levrazoxane ((R)-ICRF 186) is enzymatically hydrolysed to one-ring open intermediates by dihydropyrimidine amidohydrolase (DPHase), which is present in the liver and kidney. The radiosensitizing efficiency of (R)-Levrazoxane towards EMT6 mouse mammary tumour cells is greater than that of Dexrazoxane (HY-B0581). (R)-Levrazoxane is promising for research of liver and kidney related diseases .
    (R)-Levrazoxane
  • HY-W011527R
    Xanthosine (Standard)

    		Endogenous Metabolite Others
    Xanthosine (Standard) is the analytical standard of Xanthosine. This product is intended for research and analytical applications. Xanthosine is a nucleoside derived from xanthine and ribose. Xanthosine activates the AMPK/FoxO1/AKT/GSK3β signaling cascade. Xanthosine promotes cell proliferation and regulates blood glucose metabolism. Xanthosine increases milk production in cows and goats. Xanthosine is used in mammary stem cell and type 2 diabetes research .
    Xanthosine (Standard)
  • HY-121389
    Hexadecanamide

    Palmitamide

    		 Bacterial NF-κB PPAR Infection Inflammation/Immunology
    Hexadecanamide (Palmitamide), a fatty acid amide, has orally active anti-allergic, antioxidant, and neuroprotective effects. Hexadecanamide alleviate S. aureus-caused mastitis by depressing inflammatory response and maintaining blood-milk barrier integrity. Hexadecanamide depresses S. aureus-induced activation of the NF-κB pathway in mouse mammary epithelial cells (MMECs). Hexadecanamide activates PPARα. Hexadecanamide enhances sperm motility in vitro .
    Hexadecanamide
  • HY-147853
    B-Raf IN 8

    		Raf Cancer
    B-Raf IN 8 (compound 7g) is a potent B-Raf inhibitor, with an IC50 of 70.65 nM. B-Raf IN 8 exhibits antitumor activity against hepatocellular carcinoma (HEPG-2), colon carcinoma (HCT-116), mammary gland (MCF-7) and human prostate cancer (PC-3) cells, with IC50 values of 9.78, 13.78, 18.52 and 29.85 µM .
    B-Raf IN 8
  • HY-111846
    PROTAC ERα Degrader-2
    1 Publications Verification

    		 SNIPERs PROTACs Estrogen Receptor/ERR Cancer
    PROTAC ERα Degrader-2 comprises a IAP ligand binding group, a linker and an estrogen receptor α (ERα) binding group. PROTAC ERα Degrader-2 is an ERα degrader. Maximal ERα degradation at 30 μM concentration in human mammary tumor MCF7 cells. Degradation inducers based on cIAP1 are called specific and non-genetic IAP-dependent protein erasers (SNIPERs) .
    PROTAC ERα Degrader-2
  • HY-147852
    B-Raf IN 7

    		Raf Cancer
    B-Raf IN 7 (compound 6a) is a potent B-Raf inhibitor, with an IC50 of 110.23 nM. B-Raf IN 7 exhibits antitumor activity against colon carcinoma (HCT-116), mammary gland (MCF-7), hepatocellular carcinoma (HEPG-2), human cervical carcinoma (Hela) and human prostate cancer (PC-3) cells, with IC50 values of 7.50, 9.87, 10.57, 11.63 and 12.83 µM .
    B-Raf IN 7
  • HY-122566
    SMU127

    ZINC666243

    		 Toll-like Receptor (TLR) TNF Receptor Cancer
    SMU127 is an agonist of the toll-like receptor 1/2 (TLR1/2) heterodimer. It induces NF-κB signaling in cells expressing human TLR2 (EC50=0.55 μM) but not cells expressing human TLR3, -4, -5, -7, or -8 when used at concentrations ranging from 0.1 to 100 μM. SMU127 induces the production of TNF-α in isolated human peripheral blood mononuclear cells (PBMCs) when used at concentrations ranging from 0.01 to 1 μM. In vivo, SMU127 (0.1 mg/animal) reduces tumor volume in a 4T1 murine mammary carcinoma model.
    SMU127
  • HY-145268
    SLEC-11

    		Cadherin Cancer
    SLEC-11 is a CDH1/E-cadherin modulator that potently inhibits cell death in E-cadherin-deficient cells (EC50=8.2 μM). SLEC-11 can be used to study potential synthetic lethal therapies for gastric cancer .
    SLEC-11
  • HY-19350
    BML-210
    2 Publications Verification

    		 HDAC Apoptosis Cancer
    BML-210 is a potent HDAC inhibitor. BML-210 can inhibit the HDAC4-VP16-driven reporter signal with an apparent IC50 of ∼5 µM. BML-210 has a specific disruptive effect on the HDAC4:MEF2 interaction. BML-210 causes an increase in the G0/G1 phase. BML-210 induces apoptosis and displays antitumour activities in orthotopic mammary tumours in mice .
    BML-210